Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • View item
  • Home
  • ICR Divisions
  • Clinical Studies
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients

Thumbnail
Date
2003-03
ICR Author
Catovsky, Daniel
Matutes, Estella
Author
Parry-Jones, N
Matutes, E
Gruszka-Westwood, AM
Swansbury, GJ
Wotherspoon, AC
Catovsky, D
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Splenic lymphoma with villous lymphocytes (SLVL) is a low-grade B-cell lymphoma defined in the World Health Organization classification as the leukaemic form of splenic marginal zone lymphoma. Presenting features and response to therapy have been described, but information on prognostic factors is scanty. Clinical, laboratory and follow-up data were collected on 129 patients with SLVL to determine features predicting disease behaviour and survival. Diagnosis was made on clinical, morphological and immunophenotypic features and, where available, bone marrow and spleen histology. Median age was 69 years (range 39-90 years) and male:female ratio, 0.9. The majority had splenomegaly, but lymphadenopathy and hepatomegaly were rare. Median Hb was 11.8 g/dl, white blood cell count was 16 x 10(9)/l and platelet count was 145 x 10(9)/l; 27% of patients had monoclonal protein in serum and/or urine. While 27% of patients remained untreated, 10% transformed to high-grade lymphoma. Median follow-up was 61 months and median survival was 13 years, with 72% of patients alive at 5 years. Cox regression analysis showed that increasing age, anaemia, thrombocytopenia and lymphocytosis > 16 x 10(9)/l were independent adverse predictors of overall survival. However, only anaemia and lymphocytosis > 16 x 10(9)/l remained highly significant independent prognostic factors when only deaths due to lymphoma were analysed. Splenectomized patients fared better than those receiving chemotherapy only (P = 0.001 for SLVL deaths). We conclude that SLVL is mainly a disease of the elderly with a relatively benign course but, when treatment is required, splenectomy is beneficial.
URI
https://repository.icr.ac.uk/handle/internal/2694
DOI
https://doi.org/10.1046/j.1365-2141.2003.04165.x
Collections
  • Clinical Studies
  • Molecular Pathology
Research team
Molecular Haematology (including Cytogenetics Group and Cell Markers)
Language
eng
License start date
2003-03
Citation
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 pp. 759 - 764

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.